AmorChem invests in new treatment tools for acute myeloid leukemia
AmorChem, an early stage life sciences fund managed by Canadian venture capital firm GeneChem, has invested $1.5 million to develop new diagnostic and prognostic tools for acute myeloid leukemia. The project, which is led by Drs. Guy Sauvageau and Josée Hébert, both senior researchers and professors at the Université de Montréal, will focus on technology that helps predict how patients should be treated based on the genetic makeup of their tumor. AmorChem said it will work with the university's commercialization unit, IRIC-Commercialization of Research, to bring to market new tools that result from the project.
4 June 2014•4 mins read
